查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1609120

重症肌无力治疗市场：按类型、最终用户划分 - 2025-2030 年全球预测

Myasthenia Gravis Treatment Market by Type (Medication, Surgery), End-User (Clinics, Hospitals) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

重症肌无力治疗市场2023年估值为19.3亿美元，预计到2024年将达到20亿美元，复合年增长率为5.21%，预计到2030年将达到27.6亿美元。

在盛行率增加、诊断技术改进和治疗方法进步的推动下，重症肌无力 (MG) 治疗市场有望实现动态和显着成长。重症肌无力是一种慢性自体免疫神经肌肉疾病，其特征是波动性肌肉无力和疲劳。治疗的需要源于改善病人的生活品质和预防危及生命的情况的需要。治疗通常涉及免疫抑制剂、单株抗体和乙酰胆碱酯酶抑制剂，并应用于医院、神经科诊所和研究机构。最终用户包括希望在这一领域进行创新的医疗保健提供者、患者和製药公司。

主要市场统计
基准年[2023] 19.3亿美元
预计年份 [2024] 20亿美元
预测年份 [2030] 27.6亿美元
复合年增长率（%） 5.21%

成长是由几个关键因素推动的，包括医疗保健支出的增加、生物技术的进步以及医疗保健专业人员和患者对罕见神经系统疾病的认识提高。新疗法的进入，例如艾加替莫德和新型生物製药，带来了巨大的潜在机会。对于希望利用这一前景的公司来说，投资于针对遗传标记的药物发现和个人化医疗将是有益的。此外，与研究机构合作进行临床试验可能会促进新治疗方法的推出。

然而，其局限性包括治疗成本高、长期免疫抑制治疗的潜在副作用以及针对重症肌无力等罕见疾病的大规模临床试验的复杂性。此外，严格的监管协议可能会阻碍新药的快速核准。

创新应专注于开发副作用最小的标靶治疗、利用人工智慧进行药物发现以及提高患者对数位健康解决方案的依从性。用于早期诊断和进展追踪的生物标记研究可以大大增强治疗策略。 MG 的治疗是一个利基市场，是专业化的，需要对病理学有深入的了解并遵守法规。总体而言，市场预计将实现稳健成长，但必须仔细克服独特的挑战，以实现可持续的业务成长。

市场动态：快速发展的重症肌无力治疗市场的关键市场洞察

重症肌无力治疗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 世界老年人口的增加
    • 重症肌无力导致眼睛肿胀的病例增加
    • 治疗临床试验的增加
  • 市场限制因素
    • 治疗高成本
  • 市场机会
    • 改善医疗基础设施
    • 药物开发管道研究迅速增加
  • 市场挑战
    • 与药物相关的副作用

波特的五力策略工具驾驭重症肌无力治疗市场

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解重症肌无力治疗市场的外在影响

外部宏观环境因素在塑造重症肌无力治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解重症肌无力治疗市场的竞争状况

对重症肌无力治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵重症肌无力治疗市场供应商的绩效评估

FPNV 定位矩阵是评估重症肌无力治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製重症肌无力治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对重症肌无力治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地人口老化仍在持续
      • 重症肌无力导致眼睛肿胀的病例增加
      • 治疗临床试验的增加
    • 抑制因素
      • 治疗费用高
    • 机会
      • 改善医疗基础设施
      • 药物开发平臺研究数量快速增加
    • 任务
      • 与药物相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章重症肌无力治疗市场：依类型

  • 药物治疗
  • 外科手术

第七章重症肌无力治疗市场：依最终使用者分类

  • 诊所
  • 医院

第八章美洲重症肌无力治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区重症肌无力治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲重症肌无力治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Alexion Pharmaceutical Inc.
  • Argenx
  • Avadel Pharmaceuticals, PLC
  • Bausch Health Companies Inc.
  • Catalyst Pharmaceuticals Inc.
  • CSL Behring AG
  • F.Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer, Inc.
  • Sandoz Inc. by Novartis AG
  • Sun Pharmaceuticals Industries
  • Taj Pharmaceuticals Ltd.
  • Takeda Pharmaceuticals Company Limited
  • Troikaa Pharmaceuticals Ltd.
Product Code: MRR-0A609A26A9B8

The Myasthenia Gravis Treatment Market was valued at USD 1.93 billion in 2023, expected to reach USD 2.00 billion in 2024, and is projected to grow at a CAGR of 5.21%, to USD 2.76 billion by 2030.

The market for Myasthenia Gravis (MG) treatments is dynamic and poised for substantial growth, driven by increasing prevalence rates, enhanced diagnostic techniques, and advancements in therapeutic approaches. Myasthenia Gravis is a chronic autoimmune neuromuscular disease characterized by fluctuating muscle weakness and fatigue. The necessity for treatments stems from the need to enhance patient quality of life and prevent life-threatening conditions. Treatment typically involves immunosuppressive drugs, monoclonal antibodies, and acetylcholinesterase inhibitors, with applications in hospitals, specialized neurology clinics, and research settings. End-users include healthcare providers, patients, and pharmaceutical companies seeking to innovate in this sector.

KEY MARKET STATISTICS
Base Year [2023] USD 1.93 billion
Estimated Year [2024] USD 2.00 billion
Forecast Year [2030] USD 2.76 billion
CAGR (%) 5.21%

Growth is influenced by several key factors, including increased healthcare expenditure, advancements in biotechnology, and heightened awareness among healthcare professionals and patients regarding rare neurological disorders. The entry of novel therapies such as efgartigimod and novel biologics presents significant potential opportunities. For businesses looking to capitalize on these prospects, investing in drug discovery and personalized medicine tailored to genetic markers could prove beneficial. Moreover, partnerships with research institutions for clinical trials could expedite the introduction of new therapies.

However, the market faces limitations such as high treatment costs, potential side effects of long-term immunosuppressive therapies, and the complexity of conducting large-scale clinical trials for an orphan disease like MG. Additionally, stringent regulatory protocols can hinder the fast-track approval of new drugs.

Innovation should focus on developing targeted therapies with minimal side effects, leveraging artificial intelligence for drug discovery, and enhancing patient adherence through digital health solutions. Research into biomarkers for early diagnosis and progression tracking can significantly enhance treatment regimes. As a niche market, the nature of MG treatment is specialized, requiring a deep understanding of neurological pathophysiology and regulatory compliance. Overall, the market presents robust growth prospects but requires careful navigation through its inherent challenges to achieve sustainable business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Myasthenia Gravis Treatment Market

The Myasthenia Gravis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing geriatric population across the globe
    • Increasing cases of swollen eyes due to Myasthenia Gravis
    • Rising clinical trials for treatment
  • Market Restraints
    • High cost associated with the treatment
  • Market Opportunities
    • Improving healthcare infrastructure
    • Upsurge in the number of pipeline studies for drug development
  • Market Challenges
    • Side effects associated with drugs

Porter's Five Forces: A Strategic Tool for Navigating the Myasthenia Gravis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Myasthenia Gravis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Myasthenia Gravis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Myasthenia Gravis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Myasthenia Gravis Treatment Market

A detailed market share analysis in the Myasthenia Gravis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Myasthenia Gravis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Myasthenia Gravis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Myasthenia Gravis Treatment Market

A strategic analysis of the Myasthenia Gravis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Myasthenia Gravis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alexion Pharmaceutical Inc., Argenx, Avadel Pharmaceuticals, PLC, Bausch Health Companies Inc., Catalyst Pharmaceuticals Inc., CSL Behring AG, F.Hoffmann-La Roche AG, GlaxoSmithKline PLC, Mitsubishi Tanabe Pharma Corporation, Pfizer, Inc., Sandoz Inc. by Novartis AG, Sun Pharmaceuticals Industries, Taj Pharmaceuticals Ltd., Takeda Pharmaceuticals Company Limited, and Troikaa Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Myasthenia Gravis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Medication and Surgery.
  • Based on End-User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing geriatric population across the globe
      • 5.1.1.2. Increasing cases of swollen eyes due to Myasthenia Gravis
      • 5.1.1.3. Rising clinical trials for treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Improving healthcare infrastructure
      • 5.1.3.2. Upsurge in the number of pipeline studies for drug development
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Myasthenia Gravis Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Medication
  • 6.3. Surgery

7. Myasthenia Gravis Treatment Market, by End-User

  • 7.1. Introduction
  • 7.2. Clinics
  • 7.3. Hospitals

8. Americas Myasthenia Gravis Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Myasthenia Gravis Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Myasthenia Gravis Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alexion Pharmaceutical Inc.
  • 3. Argenx
  • 4. Avadel Pharmaceuticals, PLC
  • 5. Bausch Health Companies Inc.
  • 6. Catalyst Pharmaceuticals Inc.
  • 7. CSL Behring AG
  • 8. F.Hoffmann-La Roche AG
  • 9. GlaxoSmithKline PLC
  • 10. Mitsubishi Tanabe Pharma Corporation
  • 11. Pfizer, Inc.
  • 12. Sandoz Inc. by Novartis AG
  • 13. Sun Pharmaceuticals Industries
  • 14. Taj Pharmaceuticals Ltd.
  • 15. Takeda Pharmaceuticals Company Limited
  • 16. Troikaa Pharmaceuticals Ltd.

LIST OF FIGURES

  • FIGURE 1. MYASTHENIA GRAVIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. MYASTHENIA GRAVIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. MYASTHENIA GRAVIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MYASTHENIA GRAVIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MYASTHENIA GRAVIS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. MYASTHENIA GRAVIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. MYASTHENIA GRAVIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023